Beyond Air Inc Stock

$0.16

2.02% yesterday

Nasdaq, Jun 27, 10:06 pm CET

ISIN

US08862L1035

Symbol

XAIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Software / Internet

Industry

Standard software

Overview Dividends Analysts Charts News Strategies

Beyond Air Inc Stock price

$0.16

-6.85 97.72% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.00 2.02%

ISIN

US08862L1035

Symbol

XAIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Software / Internet

Industry

Standard software

Key metrics

Basic

Market capitalization

$14.9m

Enterprise Value

$17.7m

Net debt

$2.9m

Cash

$6.9m

Shares outstanding

82.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

4.00 | 1.04

EV/Sales

4.78 | 1.24

EV/FCF

negative

P/B

0.97

Financial Health

Equity Ratio

45.18%

Return on Equity

-343.26%

ROCE

-177.73%

ROIC

Debt/Equity

0.72

Financials (TTM | estimate)

Revenue

$3.7m | $14.3m

EBITDA

$-41.3m | $-714.0k

EBIT

$-44.5m

Net Income

$-46.6m | $-31.5m

Free Cash Flow

$-44.1m

Growth (TTM | estimate)

Revenue

219.83% | 286.23%

EBITDA

32.26% | 98.27%

EBIT

29.31%

Net Income

22.61% | 32.45%

Free Cash Flow

28.59%

Margin (TTM | estimate)

Gross

-44.91%

EBITDA

-1,115.65% | -4.98%

EBIT

-1,202.13%

Net

-1,258.43% | -219.83%

Free Cash Flow

-1,190.31%

EPS

$-0.52

FCF per Share

$-0.53

Short interest

4.45%

Employees

107.00

Rev per Employee

$30.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Beyond Air Inc Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Beyond Air Inc forecast:

9x Buy

82%

2x Hold

18%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Beyond Air Inc forecast:

Buy

82%

Hold

18%

Analyst Estimates with Stock Price Targets

Financial data from Beyond Air Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	3.71 3.71	220% 220% 100%
- Direct Costs	5.37 5.37	118% 118% 145%
Gross Profit	-1.66 -1.66	28% 28% -45%
- Selling and Administrative Expenses	26 26	30% 30% 701%
- Research and Development Expense	17 17	31% 31% 454%
EBITDA	-41 -41	32% 32% -1,114%
- Depreciation and Amortization	3.20 3.20	62% 62% 86%
EBIT (Operating Income) EBIT	-45 -45	29% 29% -1,201%
Net Profit	-47 -47	23% 23% -1,257%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Beyond Air Inc Stock News

Neutral

Seeking Alpha

●

10 days ago

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR ) Q4 2025 Earnings Conference Call June 17, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - CFO, Principal Financial Officer & Principal Accounting Officer Steven Adam Lisi - CEO & Chairman of the Board Conference Call Participants I-Eh Jen - Laidlaw & Company (UK) Ltd., Research Division Jason Hart Wittes - ROTH Capital Partners, LLC, Research Divisi...

Neutral

GlobeNewsWire

●

11 days ago

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA International distribution partnerships now provide acce...

Neutral

GlobeNewsWire

●

12 days ago

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

LungFit PH II's smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country GARDEN CITY, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on h...

More Beyond Air Inc News

Company Profile

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. It engages in the developing a nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company develops LungFit platform system, a generator and delivery system that produces nitric oxide from ambient air, eliminating the need for expensive and cumbersome cylinders. Beyond Air was founded in 2011 and is headquartered in Garden City, NY.

Head office	United States
CEO	Steven Lisi
Employees	107
Founded	2015
Website	www.beyondair.net

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now